Mitogen-activated protein kinases (MAPKs) are members of a dynamic protein kinase network through which diverse stimuli regulate the spatio-temporal activities of complex biological systems. MAPKs regulate critical cellular functions required for homeostasis such as the expression of cytokines and proteases, cell cycle progression, cell adherence, motility and metabolism. MAPKs therefore influence cell proliferation, differentiation, survival, apoptosis and development. In vertebrates, five MAPK families are regulated by MAPK kinase kinase-MAPK kinase-MAPK (MKKK-MKK-MAPK) phosphorelay systems. There are at least 20 MKKKs that selectively phosphorylate and activate different combinations of the seven MKKs, resulting in a specific activation profile of members within the five MAPK families. MKKKs are differentially activated by upstream stimuli including cytokines, antigens, toxins and stress insults providing a mechanism to integrate the activation of different MAPKs with the cellular response to each stimulus. Thus, MKKKs can be considered as 'signaling hubs' that regulate the specificity of MAPK activation. In this review, we describe how the MKKK 'hub' function regulates the specificity of MAPK activation, highlighting MKKKs as targets for therapeutic intervention in cancer and other diseases.
Introduction
Mitogen-activated protein kinases (MAPKs) are ubiquitously expressed and regulate a wide variety of functions in virtually all cell types. In vertebrates five families of MAPKs encoded by 11 different genes include extracellular signal-regulated kinase ERK1/2, c-Jun N-terminal kinase JNK1/2/3, p38a/b/d/g, ERK5 and ERK7 (Uhlik et al., 2004) . Splice variants exist for several of the MAPK proteins. MAPKs phosphorylate specific substrate proteins that regulate cell proliferation, survival, motility, metabolism, transcription and translation. MAPKs contribute to the cellular response to diverse stimuli, including growth factors, cytokines, and stresses such as toxins, numerous drugs, changes in cell adherence, osmolarity, oxygen radicals, ultraviolet light and temperature . It is therefore not unexpected that dysregulated MAPK activity is associated with a variety of pathological states, including those arising from inflammation, such as arthritis and inflammatory bowel disease (Johnson and Lapadat, 2002; Hollenbach et al., 2004) , as well as syndromes that include the uncontrolled cellular proliferation and tissue remodeling characteristic of cancer (Gollob et al., 2006) .
An understanding of how any of the arrays of stimuli that activate MAPKs can induce a specific outcome has been the goal of an intensive research effort. MAPKs are the terminal kinase in a three kinase phosphorelay module, in which MAPKs are phosphorylated and activated by mitogen-activated protein kinase kinase MKKs, which themselves are phosphorylated and activated by mitogen-activated protein kinase kinase kinase (MKKKs). Of the MAPK signaling module components that have been identified in human cells, MKKKs are the largest in number (at least 20 genes), as compared to the MKKs (seven genes) and MAPKs (11 genes) (Uhlik et al., 2004) . The numbers of each MKKK, MKK and MAPK are actually larger when splice variants are counted. Interestingly, some MKKKs can activate different MAPK modules, or activate the same module with altered duration or localization to render distinct outcomes . Given the variety of stimuli known to activate the different MAPKs, the diversity of MKKKs represents a predominant mechanism by which specificity is achieved in MAPK activation. Restated, MKKKs can route signals originating from widely differing inputs to MAPK signaling modules to provide specific functional responses. In this sense, MKKKs represent organizational nodes or 'hubs' that integrate responses to provide specificity in MAPK activation. Figure 1 illustrates a wiring diagram for four of the 20 MKKKs. MEKKs have significant homology in their kinase domains (see below) and differentially regulate more than one MAPK (Fanger et al., 1997; Yujiri et al., 1998; . The connections in the wiring diagram represent protein interactions based on published data in PubMed. In addition, targeted gene knockouts in mice for MEKK1-4 have been characterized (Yujiri et al., 1998; Garrington et al., 2000; Yang et al., 2000; . The knockout phenotypes for MEKK1, 2, 3 and 4 clearly define specific modules within the connections map that have defined essential physiological roles for each MEKK. For such a connections map a module can be defined as a discrete unit of function that is separable from other components of the system. An example is the MEKK3-OSM-KRIT module that regulates cerebral vascular integrity. Mutation of OSM or KRIT results in the disease cerebral cavernous malformations (CCM) that affect one in 200 people in the United States (Sahoo et al., 1999; Zawistowski et al., 2005) . One can imagine the complexity of such a connections map for all 20 MKKKs. In this review, we examine the mechanisms by which MKKKs integrate signals from diverse origins to elicit specific functional outcomes from MAPK activation.
Scaffold proteins organize MKKK-MKK-MAPK modules for specific outcomes MAPK signaling complexes elicit specific signaling outcomes in part by binding to scaffold proteins to regulate the location and duration of MAPK activation.
For example, the MKKK MEKK3 binds to and activates the MKK, MEK5 leading to ERK5 activation (Nakamura and Johnson, 2003) , but MEKK3 may also directly bind the scaffold OSM, thereby activating a different MKK, MKK3, thus regulating p38 MAPK activity in response to Rac-induced signals (Uhlik et al., 2003) . Importantly, OSM binds to MEKK3 and MKK3, but not MEK5, promoting distinct MAPK activation from a single MKKK. The modularity of MKKK-MKK-MAPK signals, which is often controlled by scaffolding proteins localized in specific subcellular locations (i.e., focal adhesions versus early endosomes), regulates the spatio-temporal activation of MAPKs by different stimuli that are routed through specific MKKKs, thereby coordinating the induced MAPK response.
MKKK function by group
The dendrogram displayed in Figure 2 represents a categorization of MKKKs based on sequence homology within their kinase domains. For the purpose of functional comparisons, we have subdivided the MKKKs into six groups: mitogen-activated protein/ERK kinase kinases MEKK, mixed lineage kinase MLK, Raf, thousand and one amino acid TAO/tumor progression locus 2 Tpl2, as well as MOS and TGF-bactivated kinase 1 TAK-1. Interestingly, only six of the 20 MKKKs clearly regulate the ERK1/2 pathway. In Figure 1 Connections map showing protein interactions for MEKK1, 2, 3 and 4. The connections map illustrates MEKKs as functional signaling hubs for integrating multiple upstream inputs into the control of specific MAPKs. The maps were created from PubMed data base searches and filtering of data based on the phenotypes of mice having targeted gene disruption or kinaseinactivating knockins of each MEKK. Color codes represent different classes of proteins or pathways that feed into the four MEKKs. Green represents scaffold proteins and receptors that utilize the scaffolds in stimulating a response. Pink represents tyrosine kinases. Light blue represents serine-threonine kinases. Red represents receptors and regulators of receptor response. Yellow represents GTPases.
Role of MKKKs in signal integration
BD Cuevas et al contrast, at least 12 MKKKs regulate the JNK pathway and nine MKKKs regulate the p38 pathway. The greater number of MKKKs regulating the stressactivated JNK and p38 pathways is probably indicative of the necessity of cells to be able to respond to many different stress-stimuli with the activation of JNK and/ or p38. What also stands out in this comparison is that five of the six MKKKs that regulate ERK1/2 do so apparently without activating JNK, p38 or ERK5. With respect to Raf kinases, this selectivity likely reflects the important role of ERK1/2 in regulating cell proliferation in response to growth factor receptor tyrosine kinases (Wellbrock et al., 2004) . Tpl2 activation of ERK1/2 is a critical response in macrophages to lipopolysaccharide (LPS) for the innate immune response to infection (Dumitru et al., 2000) . The activation of ERK5 is even more restricted than that of ERK1/2. MEKK2 and MEKK3 are the only MKKKs shown to physiologically activate the MEK5-ERK5 module (Nakamura and Johnson, 2003) . This selectivity of only two MKKKs regulating ERK5 activation suggests a restricted function of the ERK5 pathway in cells. Figure 3 shows the functional domains encoded in specific MKKKs. Other than the kinase domain that was used to categorize MKKK groups, there are several unique characteristics for specific groups of MKKKs. All members of the MLK group have an Src-homology-3 (SH3) domain and at least one leucine zipper (LZ) domain (Gallo and Johnson, 2002) . Four members of the MLK group have a Cdc-42/Rac-interactive binding Crib domain to bind Cdc42 and/or Rac. MEKK1 is the only MKKK to have a ring domain, ubiquitin interaction motif and caspase cleavage site . MEKK2 and MEKK3 uniquely have Phox/Bem 1p (PB1) domains that heterodimerize with the PB1 domain in MEK5 providing specificity in regulating the ERK5 pathway (Nakamura and Johnson, 2003) . ASK1 is the only MKKK with a thioredoxin-binding region that, although not a true 'domain', promotes apoptosis signal-regulating kinase (ASK1) specificity in responding to the intracellular redox state (Hayakawa et al., 2006) .
Owing to space restrictions, we have limited historical details of MKKK discovery and attempt to focus instead on more recent developments in delineating the role of MKKKs in integrating signals for spatiotemporal control of specific cellular functions.
MEKK group
MEKKs are each capable of regulating multiple MKKs leading to activation of at least two different families of MAPK (Figures 1 and 2 ), thus providing a clear example of the MKKK-as-hub concept. MEKK1 regulates both JNK and ERK1/2 activation, MEKK2 controls JNK and ERK5, MEKK3 activates ERK5 and p38, and MEKK4 regulates both JNK and p38 activation. Using mouse knock-out/knock-in models, our group and others have discovered striking Role of MKKKs in signal integration BD Cuevas et al differences in the requirement for MEKK expression during development. MEKK3 knockout is embryo lethal, displaying inadequate fetal-maternal vascularization (Yang et al., 2000) , whereas loss of MEKK4 activity is largely perinatal lethal, and is associated with defective neural tube closure . In contrast, both MEKK1 and MEKK2 are developmentally dispensable, with recent evidence suggesting that losses of these proteins are associated with impaired tissue remodeling associated with wound healing and homeostasis Yamashita et al., 2005; Deng et al., 2006) . These models indicate that, while other MKKKs also regulate activation of these MAPK modules, the MEKKs each control one or more cellular functions that are not redundant and thus not compensated for by other MKKKs.
MEKK1 was the first of this group to be identified, and functional analysis revealed MEKK1 capable of association with and activation by small G proteins; a theme common among MKKKs (Fanger et al., 1997; Gallagher et al., 2004) . Of interest is the link between MEKK1 and Rho family small GTPases, especially in light of our finding that MEKK1 regulates cell migration. Immediately amino-terminal to the MEKK1 kinase domain is a region that bears a weak homology to a consensus CRIB domain and MEKK1 association with Rac maps to this general region of the protein (Fanger et al., 1997) . Gallagher et al. ( 2004) later demonstrated that MEKK1 forms a complex with RhoA, with the RhoA-binding region located within a distinct amino-terminal region of the protein.
RhoA regulates focal adhesion formation, and we found MEKK1 to localize to focal adhesions, where it forms a complex with focal adhesion kinase (FAK) and regulates ERK1/2-dependent activation of the proteinase calpain . Calpain regulates focal adhesion turnover and cell migration (Huttenlocher et al., 1997) . 
Role of MKKKs in signal integration
BD Cuevas et al activin-dependent epithelial cell migration. Collectively, these studies show MEKK1 to be a nexus for diverse signals that influence cell migration. JNK phosphorylates the transcription factor component protein c-Jun, which can subsequently dimerize to form the activator protein 1 (AP-1) transcription factor and thereby regulate gene expression (Karin and Gallagher, 2005) . Specific MKKKs that activate JNK are therefore predicted to influence AP-1-dependent gene expression. We have recently found that MEKKs can also impact gene expression by regulating the availability of AP-1 transcriptional complex component proteins. In addition to c-Jun, these component proteins can include JunB and JunD, where Jun proteins can form functional dimers with each other or with Fos family proteins (c-Fos, FosB, Fra1 and Fra2), ATFs (ATF-1, ATF-2) or Maf. We found that expression of JunB and Fra-2 was markedly increased in MEKK1-deficient mouse fibroblasts Xia et al., 2007) . Interestingly, we discovered that MEKK1 controls JunB expression at the transcriptional level, but regulates c-Jun and Fra2 availability post-translationally via control of c-Jun and Fra2 protein stability. c-Jun and Fra2 are subject to ubiquitin-dependent degradation, and it was observed that c-Jun and Fra2 ubiquitination was inhibited and c-Jun and Fra2 protein stability enhanced in MEKK1-deficient fibroblasts. MEKK1 contains an amino-terminal RING domain that functions as an E3 ubiquitin ligase (Figure 3 ), which we have found to regulate MEKK1 kinase activity, but not to directly ubiquitinate Fra2 Cuevas et al., 2005) . MEKK1 does appear able to directly ubiquitinate c-Jun (Xia et al., 2007) .
MEKK1-dependent regulation of transcription factor expression was found also in a very different cellular context, as the stability of c-Jun in MEKK1 mutant T cells was likewise dysregulated. MEKK1 promotes activation of the E3 ubiquitin ligase Itch, which ubiquitinates c-Jun, leading to proteasome-mediated c-Jun degradation (Gao et al., 2004) . By regulating the repertoire of AP-1 transcription factor components, MEKK1 influences expression of AP-1-dependent genes such as urokinase plasminogen activator (uPA), a serine protease important in tissue remodeling and tumor progression . These studies indicate that MEKK1 can respond to widely different signals in diverse cell types to regulate the composition and activity of transcription factors, which in turn strongly influences the functional outcome of MAPK signaling.
MEKK2 also influences AP-1 component availability. MEKK2 regulates ERK5 and JNK in fibroblasts in response to growth factors such as EGF and fibroblast growth factor (FGF-2), and these MAPK modules regulate the expression and activation of both Jun and Fos proteins Kesavan et al., 2004) . MEKK2 forms a signaling complex with the scaffold protein Lad that promotes activation of MEK5. MEKK2 also has been reported to be capable of dimerization via the kinase domain for transphosphorylation to increase MEKK2 kinase activity. We have shown that MEKK2À/À fibroblasts are inhibited in the induction of c-Jun, Fra-1 and Fra-2 mRNA in response to FGF-2 (Kesavan et al., 2004) . Among the genes known to be AP-1-dependent are the cytokines tumor necrosis factor (TNFa), interleukin-1a (IL-1a), IL-1b, and IL-6, and FGF-2-induced expression of these proteins is markedly reduced in MEKK2-deficient fibroblasts. Our studies with MEKK2-deficient bone marrow and ES-derived mast cells confirm that MEKK2 regulates inflammatory cytokine expression in multiple cell types (Garrington et al., 2000; Wei et al., 2003) . While both MEKK1 and MEKK2 control expression of AP-1 components, knockout of each renders a distinct phenotype.
MEKK3 is 95% conserved in its kinase domain and 55% conserved in overall amino-acid sequence to MEKK2 (Blank et al., 1996) . MEKK3 regulates the ERK5 and p38 MAPK pathways, whereas MEKK2 regulates JNK and ERK5. Using yeast two-hybrid screening, our group discovered that MEKK3, but not MEKK2, binds to the scaffolding protein Osmosensing Scaffold for MEKK3 (OSM) for Rac-dependent activation of the p38 pathway (Uhlik et al., 2003) . The human homolog of OSM was independently identified by Liquori et al. (2003) as the second locus in a screen for genes linked to the vascular disorder CCM, and thus was also named CCM2. MEKK3 is reported to bind TNF receptor associated factor TRAF6 and TRAF7 and is proposed to regulate IL-1R and Toll-like receptor TLR4 signaling for the activation of nuclear factorkappaB (NF-kB) and p38 and possibly JNK (Huang et al., 2004; Xu et al., 2004) . MEKK3 also regulates AP-1 activity that is enhanced by co-expression of TRAF6 or TRAF7. Huang et al. (2004) have reported that MEKK3 is required for IL-1R and LPS-induced IL-6 production in mouse fibroblasts, but little other characterization of cytokine regulation has been reported for MEKK3.
ERK5 is a primary response pathway for the regulation of MEF2 transcription factors and the control of c-Jun expression (Kato et al., 1997 (Kato et al., , 2000 . MEKK2 and MEKK3 are the predominant MKKKs defined to regulate ERK5 (Nakamura and Johnson, 2003) . Gotoh et al. (2001) used overexpression assays to assert that the mixed lineage kinase ZAKa could also activate ERK5, but that finding remains controversial, and MEKK2 and MEKK3 are the only MKKKs shown to interact physically with and activate the MEK5-ERK5 module, where MEK5 is the MKK that phosphorylates and activates ERK5 (Sun et al., 2001 . Mice that express an activated mutant MEK5 in cardiomyocytes display cardiac hypertrophy and die at 8 weeks of age (Nicol et al., 2001) , suggesting that stringent control of ERK5 activation is important in cardiac homeostasis. The ERK5 knockout is embryonic lethal similar to the MEKK3 knockout with failure in angiogenesis and abnormal cardiac development (Regan et al., 2002; Sohn et al., 2002; Yan et al., 2003) . Conditional knockout of ERK5 in adult animals caused vascular failure resulting in death of the animals (Hayashi et al., 2004) . As MEF2 and c-Jun are known to regulate the expression of a number of cytokines, the genetic evidence strongly supports a role for ERK5 in the regulation of the cytokine environment required for functional vascularization and maintenance. ERK5 also physically interacts with PPARg that may also contribute to regulation of the vascular endothelium (Akaike et al., 2004) .
We have found that MEKK2 and MEKK3 regulate MEK5 activation through heterodimerization of the MEKK2 (or MEKK3) and MEK5 PB1 domains (Nakamura and Johnson, 2003) . MEKK2, MEKK3 and MEK5 are the only MKKKs and MKK that encode PB1 domains, providing PB1 domain-dependent selectivity in the organization of an MEKK2 (or MEKK3)-MEK5-ERK5 signaling module. MEKK2 (MEKK3)/MEK5 complexes selectively activate ERK5, but not p38 or JNK (Nakamura and Johnson, 2003) . Our studies indicate that the PB1 domains encoded in MEKK2, MEKK3 and MEK5 control the ERK5 pathway, and this is unique among MAPK phosphorelay modules. PB1 domain-dependent MEKK2/3-MEK5 heterodimers provide a spatially organized signaling complex primed to activate ERK5 in response to activation of MEKK2 or MEKK3.
MEKK4 is a less characterized MEKK with the C-terminal kinase domain having approximately 55% amino-acid homology to the kinase domains of MEKK1, MEKK2 and MEKK3 (Gerwins et al., 1997) . Upon activation, MEKK4 selectively phosphorylates MKK3, MKK4 and MKK6 leading to the activation of both JNK and p38. MEKK4 is strongly expressed in the developing embryo and plays an essential role in embryonic development Chi et al., 2005) . Loss of MEKK4 kinase activity through gene deletion or expression of a kinaseinactive MEKK4 results in embryonic lethality due to severe birth defects including neural tube and skeletal defects Chi et al., 2005) . Exencephaly in MEKK4 knock-out or knock-in mice was shown to be associated with enhanced apoptosis in the neural tube and a loss of JNK and p38 activation Chi et al., 2005) . MEKK4 binds both Rac and Cdc42, and kinase-inactive MEKK4 was found to block Rac and Cdc42-mediated JNK activation (Fanger et al., 1997; Gerwins et al., 1997) . More recently, novel MEKK4 binding partners have been identified, including TRAF4, GADD45, Axin and coiled-coil-D1X1 CCD1. The embryonic adaptor TRAF4 binds the kinase domain of MEKK4, promoting MEKK4 oligomerization and signaling to JNK . Remarkably, the phenotype of TRAF4 knockout mice is strikingly similar to that of MEKK4 kinase-inactive knock-in mice suggesting that they work in a common pathway during embryonic neural tube and skeletal development (Regnier et al., 2002; . The small growth arrest and DNA damage-inducible genes (GADD45) a, b and g proteins bind the N-terminus of MEKK4 (Takekawa and Saito, 1998) . This binding is thought to release the kinase domain of MEKK4 from its autoinhibitory N-terminus leading to enhanced MEKK4 kinase activity. Similar to Rac and Cdc42, the large scaffolding protein Axin binds both MEKK1 and MEKK4, albeit at different positions along the Axin protein (Luo et al., 2003) . Both of the MKKKs are thought to be essential for Axin signaling to JNK. Interestingly, MEKK4 also binds the DIX domain containing protein CCD1 that is thought to inhibit JNK activation by Axin and Dvl (Wong et al., 2004) . The physiological role of these interactions is unknown.
ASK1 is activated by reactive oxygen species (ROS) generated in response to cellular stresses, cytokine stimulation and LPS exposure. When the cell is at rest, ASK1 forms a homo-oligomer via its C-terminal coiledcoil domain. The redox sensitive protein thioredoxin is bound to the N-terminus of ASK1, maintaining the inactive state of ASK1. Exposure of cells to ROS oxidizes thioredoxin, causing it to dissociate from ASK1 and thus releasing ASK1 from inhibition (Hayakawa et al., 2006) . Active ASK1 phosphorylates and activates MKK4, MKK7, MKK3 and MKK6 leading to the activation of JNK and p38 (Ichijo et al., 1997) . Mice lacking ASK1 are viable, and ASK1-deficient embryonic fibroblasts retain normal transient activation of JNK and p38 in response to H 2 O 2 À and TNFa (Tobiume et al., 2001 ). However, ASK1-deficient fibroblasts show marked deficits in sustained activation of JNK and p38 by these stimuli, and similarly treated ASK1 À/À splenocytes and dendritic cells both show impaired ability to sustain p38 activity (Tobiume et al., 2001) . Further, ASK1
À/À mice have reductions in LPS-stimulated TNFa production and are resistant to LPS-induced septic shock (Ichijo et al., 1997; Matsuzawa et al., 2005) . This regulation of ASK1 by LPS is through the LPSstimulated MyD88/TRAF6-dependent pathway that is essential for the induction of inflammatory cytokines, indicating that ASK1 plays a critical role in regulation of the innate immune system.
MLK group
MLKs consist of seven different members that, when transiently overexpressed in cells, all activate JNK (Gallo and Johnson, 2002) . Based on domain structure and sequence similarity, the MLK family can be further divided into the MLKs, DLKs (dual leucine zipperbearing kinases) and ZAK (Zipper-sterile-alpha motif kinase) subgroups. The MLK subgroup containing MLK1, MLK2, MLK3 and MLK4 share a common domain structure including an amino-terminal SH3 domain, kinase domain, LZ region and a CRIB motif. The DLK and ZAK subgroups lack the SH3 and CRIB motifs, but they all contain similar kinase domains and LZ regions. In addition, ZAKa is unique in that it also contains a sterile-a motif that is thought to mediate homo or hetero-dimerization. As described above, all MLKs have been shown to activate the MKKs upstream of JNK. Some MLKs have been demonstrated in transient overexpression assays to activate additional MAPKs including p38 and ERK and to promote the activation of the NF-kB pathway (Gallo and Johnson, 2002) . For example, MLK3 has been shown to activate JNK, p38, ERK, and NF-kB (Gallo and Johnson, 2002) . Whereas DLK has been shown to activate JNK and p38, but not ERK (Gallo and Johnson, 2002) . Additional studies are required to determine the significance of MAPK selectivity to cell function in assays using RNAi and other methods that do not involve overexpression.
Of all the MLKs, targeted gene deletion of only MLK3 has been reported. MLK3-deficient mice are viable and fertile with only a mild defect in the epidermal tissue of the dorsal midline (Brancho et al., 2005) . With most of the stimuli tested including UV irradiation, sorbitol, anisomycin and ceramide, signaling to JNK and p38 was normal in MLK3-deficient fibroblasts. However, a selective reduction in TNFastimulated JNK activation was observed in MLK3-null cells, whereas p38 and ERK were not inhibited.
MLKs have been intensely studied for their role in controlling neuronal apoptosis. Small molecule inhibitors of MLKs have significant neuro-protective action in in vitro and animal models of neuronal apoptosis (Lund et al., 2005) . CEP-1347, an indolocarbazole that is a derivative of the natural product K252a from the culture broth of the K252 strain of Nocardiopsis bacteria, inhibits MLKs and was well tolerated in human trials . The inhibitor has not performed well in trials for neurodegenerative disorders such as Parkinson's disease (Waldmeier et al., 2006) .
Raf group
Raf is the MKKK component of the canonical Ras-Raf-MEK-ERK1/2 pathway. Raf phosphorylates and activates MEK1 and MEK2, which can then activate ERK1/2 to phosphorylate both cytoplasmic and nuclear targets (Wellbrock et al., 2004) . ERK1/2 activation and subsequent translocation to the nucleus promotes the phosphorylation of transcription factors, including the Ternary Complex Factor ETS-domain transcription factors that are required for growth factor-induced expression of the AP-1 component c-Fos (Whitmarsh et al., 1995) . The Raf pathway regulates a diverse set of functions, including cell migration, proliferation, survival and differentiation (Beeram et al., 2005) . The Raf proteins (A-Raf, B-Raf, and c-Raf or Raf-1) have been extensively characterized, including several B-Raf isoforms that are produced via alternative splicing. c-Raf is ubiquitous and A-Raf is also widely expressed with higher expression in urogenital organs, whereas B-Raf is highly expressed in neuronal tissues and to a lesser extent in many other tissues (Wellbrock et al., 2004) . Raf expression is required for development, as mouse embryos deficient in either B-Raf or c-Raf die before day E12.5, and A-Raf-deficient mice die perinatally at 1-3 weeks of age, indicating that the three Raf proteins are not functionally redundant (Wellbrock et al., 2004) . This was confirmed when A-Raf was placed under the control of the B-Raf locus in a gene knock-in model, the resultant mice displayed deficits in cortical neuron migration and survival (Camarero et al., 2006) . The Raf proteins all contain three highly conserved regions (CR) (Figure 3) . The amino-terminal CR1 mediates binding to Ras, CR2 is subject to phosphorylation that regulates Raf activity and the kinase domain is encoded in the carboxyl-terminal CR3 (Wellbrock et al., 2004) . The Raf signaling module becomes activated in response to growth factor stimulation and subsequent Ras activation. GTP-bound Ras binds and thereby recruits Raf to the membrane, where it is subject to both phosphorylation at multiple residues that promote activation and dephosphorylation of an inhibitory serine to induce full activation (Wellbrock et al., 2004) . Although many of these phosphorylation sites are common to all three proteins, some specific differences have been shown to impact kinase activity suggesting that kinase activity regulation differs between the three Rafs. For example, one of the positive regulatory serines subject to inducible phosphorylation in c-Raf is constitutively phosphorylated in B-Raf (Wellbrock et al., 2004) . Further, c-Raf activation also requires phosphorylation of a nearby tyrosine, yet the corresponding residue in BRaf is an aspartate, providing a charged amino acid that may mimic phosphorylation at this site. These proteinspecific differences have led to the hypothesis that B-Raf is poised to drive pathway activation and cellular transformation (Beeram et al., 2005) . Although c-Raf activity has recently been shown to be subject to feedback regulation, it is unclear at this point if B-Raf is similarly regulated (Dougherty et al., 2005) .
As with other MKKK groups, Raf association with assorted scaffold proteins has greatly increased our understanding of the spatial regulation of Raf module signaling. Raf binds to the scaffold kinase suppressor of ras (KSR) in response to activation of receptor tyrosine kinases, whereas b-arrestin is a scaffold that associates with activated G protein-coupled receptors (Morrison and Davis, 2003; Johnson et al., 2005) . KSR, b-arrestin and MP-1 facilitate Raf-dependent ERK1/2 activation at the plasma membrane, endosome and late endosome, compartments respectively . Further, activated ERK1/2 can readily dissociate from KSR and localize to the nucleus to phosphorylate target proteins, whereas endosomal localization of ERK1/2 complexed with b-arrestin is more persistent. These findings suggest that Raf/scaffold signaling complexes can integrate signals from diverse stimuli for spatiotemporal control of ERK1/2, thereby regulating access to specific substrates and thus specific ERK1/2 function. TAO/Tpl2 group TAO1 and related protein TAO2 were identified in degenerate oligonucleotide-based searches for mammalian homologues of the yeast kinase Ste20 (Hutchison et al., 1998; Chen et al., 1999) . Both were found to activate MKK3 and MKK6 in vitro and co-immunoprecipitate with MKK3 from cell lysates. TAO1/2 overexpression results in phosphorylation and activation of p38, but further studies have not been forthcoming and the biological role and significance of these MKKKs are poorly understood.
Tpl2 is functionally linked to signaling from the TNF and families. Tpl2 overexpression is highly oncogenic in mice, but Tpl2-deficient mice are viable and appear indistinguishable from littermates (Dumitru et al., 2000) . Tpl2-deficient mice produce reduced levels of TNFa in response to LPS injection, and are resistant to LPS/D-galactosamine-induced pathology. This protective phenotype was found to be due to a reduction in LPS-induced ERK1/2 activity that inhibited the translocation of TNFa mRNA to the cytoplasmic translational machinery (Dumitru et al., 2000) . ERK1/2 activation in Tpl2-deficient bone marrow-derived macrophages stimulated with either LPS or antibodies specific for the TNFR family member CD40 is markedly inhibited compared with cells from wild-type mice (Eliopoulos et al., 2003) . In addition to MAPK activation, LPS and CD40 stimulation both induce NF-kB activity, and the NF-kB activator IKKb is required for Tpl2 activation (Cho et al., 2005) . Interestingly, inactive Tpl2 has been proposed to bind NFkB/ p105, and it is the IKKb-mediated phosphorylation and consequent degradation of p105 that releases Tpl2 to phosphorylate MKK1/2 (Parameswaran et al., 2006) . Tpl2 associates with the RING domain-containing scaffold TRAF6 in response to CD40 ligation, and thus is part of a complex that coordinates both MAPK and NF-kB activation (Eliopoulos et al., 2003) .
Tpl-2 was isolated from Moloney leukemia virusinduced rat thymoma cells, and it was determined that provirus integration into the gene leads to the expression of a transforming truncated protein that confers a growth advantage to the affected cells (Patriotis et al., 1993) . Given the nature of its discovery, it is surprising that there have been few reports concerning the role of Tpl-2 in human tumors. In studies with small sample populations, Tpl-2 was found to be overexpressed without gene amplification in some large granular lymphocyte proliferative disorders (Christoforidou et al., 2004) , whereas Sourvinos et al. (1999) detected gene amplification and corresponding increased Tpl-2 expression in some human breast cancers.
TAK1
TAK1 is activated in response to IL-1b, TNFa, and LPS stimulation (Irie et al., 2000; Takaesu et al., 2003) . In response to these pro-inflammatory stimuli, active TAK1 forms a complex with an accessory protein TAB1 (Brown et al., 2005) , and activated TAK1 phosphorylates MKK4 and MKK6, thereby promoting JNK and p38 activation, respectively (Shim et al., 2005) . TAK1 signaling complexes include the adaptor proteins TAB2 and TAB3, as well as the E3 ubiquitin ligase/ scaffold protein TRAF6 (Wang et al., 2001 ). This complex is required for ubiquitin-dependent phosphorylation of IKK that is necessary for IkB degradation and consequent NFkB release to the nucleus in response to TNFa (Kanayama et al., 2004) . JNK, p38 and NFkB pathways all regulate cytokine expression, thus TAK1 was predicted to play an important role in cytokinemediated processes, including inflammation. TAK1 deficiency is embryo lethal (Shim et al., 2005; Omori et al., 2006) , and TAK1-deficient mouse embryo fibroblasts show decreased IL-1b-induced IL-6 expression (Sato et al., 2005) and TAK1-deficient keratinocytes display reduced survival when treated with TNFa (Omori et al., 2006) . The in vivo role of TAK1 in inflammation is not clear at this point, though recent evidence from an epithelium-targeted conditional TAK1 knockout supports the hypothesis that TAK1 regulates one or more inflammatory functions (Omori et al., 2006) . In this model, mice with TAK1-deficient keratinocytes develop a severe postnatal inflammation associated with increased levels of inflammatory cytokines with concurrent keratinocyte apoptosis. In addition to a role in inflammation, defective vascularization of TAK1-deficient embryo and yolk sac suggests that TAK1 also regulates vascular development (Jadrich et al., 2006) . While direct in vivo evidence of TAK1 regulation of gene expression is limited, the biochemical data strongly suggest that TAK1 influences expression of AP-1 and NF-kBdependent genes. Intriguingly, this evidence also suggests that regulation of LPS-induced MAPK activity involves the combined function of at least three MKKKs, with Tpl2 necessary for ERK1/2 activation, and a requirement for TAK1 and ASK1 to regulate transient and long-term JNK/p38 activity, respectively.
Mos
The smallest of the MKKK group identified thus far is cMos, the cellular homolog of v-Mos that regulates ERK1/ 2 activation in Xenopus and mammalian oocyte development (Yew et al., 1993; Sagata, 1997) . Progesterone induces c-Mos expression and concurrent oocyte meiosis (Yue and Ferrell, 2006) . Control of c-Mos protein stability is a major regulatory mechanism, with c-Mos subject to ubiquitination and subsequent degradation. Castro et al. (2001) demonstrated that Cdc2 could phosphorylate and stabilize c-Mos in Xenopus oocytes, but the identity of an upstream kinase activator of c-Mos remains unclear. In addition to post-translational regulation, c-Mos expression is controlled at the translational level by a regulatory upstream open reading frame (Willis, 1999) . Constitutive c-Mos expression transforms mouse fibroblasts, and some studies of non-small-cell lung carcinoma have indicated that c-Mos overexpression is prevalent in this tumor type (Gorgoulis et al., 2001) , although the significance of this finding is not clear at this time.
c-Mos has been found to associate with and phosphorylate MKK1 in vitro (Chen and Cooper, 1995) . The c-Mos/MKK1 complex results in ERK1/2 activation, and has been associated with the phosphorylation and concurrent stabilization of the AP-1 component c-Fos (Okazaki and Sagata, 1995) . Thus, it appears likely that c-Mos mirrors other MKKKs in its ability to influence gene expression through control of the availability and activity AP-1 component proteins.
MKKKs in cancer
Raf pathway in transformation/tumorigenesis. c-Raf is the cellular homolog of the v-Raf viral oncogene. Raf activation of MAPK signaling can induce cellular proliferation, and thus uncontrolled Raf activity would be predicted to be important in hyperproliferative syndromes such as cancer. Compelling evidence of Raf involvement in tumorigenesis has recently come to light as large-scale efforts to determine the DNA sequence of raf genes in tumor cell lines and primary tumor samples has revealed the prevalence of Raf mutations in cancer. Davies et al. (2002) found B-Raf to be mutated in >60% of malignant melanomas, and other studies have determined that it is frequently mutated in cancers of the thyroid, colon and ovary, and is mutated at a lower frequency in a variety of other cancers (Beeram et al., 2005) . A substitution of glutamate for valine at amino acid 599 in the kinase domain accounts for about 90% of all observed B-Raf mutations (Wellbrock et al., 2004; Beeram et al., 2005) . This mutation results in a marked increase in the basal kinase activity of B-Raf, constitutive ERK1/2 activation and transformation of NIH3T3 cells (Beeram et al., 2005) . Importantly, an identical mutation in the corresponding valine residue in c-Raf results in a much more modest increase in kinase activity (Beeram et al., 2005) . Oka et al. (1995) reported a high incidence of c-Raf mutations (55%) in a small survey of primary renal cell carcinomas (RCC). Consistent with this older report, recent data from a clinical trial that included the c-Raf inhibitor BAY 43-9006/Sorafenib showed a promising response rate in patients with RCC (Ratain et al., 2006) . Sorafenib is a competitive inhibitor of ATP binding in the c-Raf catalytic domain that is reported also to inhibit both wild type-B-Raf and V599E B-Raf (Beeram et al., 2005) . Surprisingly, results from a phase II trial of Sorafenib in malignant melanoma indicated that the tested regimen of Sorafenib alone had negligible efficacy in treating melanoma, suggesting that other factors, such as the non-Raf inhibitor targets, are important in the response observed in RCC . Further, Sorafenib appears to target both the Plateletderived growth factor and Vascular endothelial growth factor tyrosine kinase receptors (Larkin and Eisen, 2006) , possibly providing an explanation for its efficacy in RCC.
A-Raf is rarely mutated in human cancers or cell lines. Indeed, when Lee et al. (2005) examined 60 human cancer cell lines of various origins and 324 primary human tumor tissue samples of various origins, only the leukemia cell line MOLT-4 was found to harbor an A-Raf mutation. It is possible this one A-Raf mutation is a polymorphism unrelated to any oncogenic mutation in the kinase. Not surprisingly, this contrast in cancer-associated mutation frequency between A-Raf and B-Raf mirrors the difference in activity between the two isoforms, as A-Raf displays the lowest kinase activity of the three isoforms (Beeram et al., 2005) .
MEKK1 regulates tissue remodeling important in invasion. The dual roles of MEKK1 as regulator of cell migration and AP-1-dependent protease expression suggested that ablation of MEKK1 expression would inhibit tumor metastasis. This hypothesis was based on the functional requirements of tumor cells to establish a secondary tumor, specifically that a tumor cell must detach from the primary tumor mass, invade the adjacent tissue stroma, and migrate to blood vessels or lymphatic ducts to gain access to potential host tissues throughout the body (Fidler, 1991) . These functions are regulated by cell signaling networks, and thus inhibition of an essential pathway would be predicted to reduce or block metastasis. We had demonstrated MEKK1 to regulate cell migration and protease expression, and tumor cell invasiveness requires both tumor cell migration and localized protease activity to degrade matrix barriers and move into the surrounding tissue stroma. Thus, we predicted MEKK1-null tumor cells would be less invasive. In a transgenic model of metastatic breast carcinoma, we observed that the growth and multiplicity of MEKK1-null mammary tumors was indistinguishable from tumors in wild-type littermates, but the formation of lung metastases in MEKK1-deficient mice was markedly delayed (Cuevas et al., 2006) . The delayed metastasis was associated with prolonged integrity of the basement membrane surrounding tumor cell-filled ducts. Importantly, this delay was associated with a similar delay in the dissemination of tumor cells to the lungs, indicating that the altered timing of metastases development was not due to inhibited growth in the MEKK1-deficient lung. Subsequent comparison of wild-type and MEKK1-deficient tumors revealed the tumors to be histologically similar in many respects, showing that loss of MEKK1 did not alter the course of tumorigenesis or inhibit primary tumor growth. MEKK1-deficient tumors displayed reduced uPA expression compared to tumors from wild type littermates. Finally, MEKK1 knockdown in invasive human breast carcinoma cells recapitulated the phenotype, showing reduced uPA expression, cell migration, and invasiveness. Thus MEKK1 influences tumor progression via control of cellular functions associated with tissue remodeling.
Another system wherein uPA expression and invasion play critical roles is vascular injury, which induces a tissue remodeling response that results in intimal hyperplasia. Using an arterial ligation model, Li et al. (2005) recently demonstrated that this intimal hyperplasia was significantly reduced in MEKK1-deficient mice, thereby providing another example of MEKK1 regulating processes critical for tissue remodeling. Interestingly, ASK1 has also been implicated in regulating this process (Izumi et al., 2003) . As described earlier, ASK1 differs from MEKK1 in that it regulates both JNK and p38 activation, and in this study ASK1-deficient cells displayed defective proliferation and migration. Thus two different MKKKs impact tissue remodeling via control of distinct functions. These data highlight the intriguing possibility that MKKKs can be targeted to block specific MAPK-dependent functions as an alternative to inhibition of the MAPK itself, thereby circumventing the undesirable side effects predicted to result from MAPK inhibition.
Concluding remarks
Although inhibition of MAPK-dependent functions such as cell migration and protease expression may be desirable in the treatment of disease, the therapeutic application of MAPK inhibitors is likely to be fraught with problems due to inhibition of vital functions unrelated to the disease. The paradigm of MKKKs as signaling hubs is exciting, as they represent potential targets for development of inhibitors that block stimulus-specific MAPK-dependent cell function, thus circumventing blanket MAPK inhibition. Much remains to be learned about the inducible gene expression controlled by individual MKKKs before it will be possible to target MKKKs to selectively inhibit the desired genes and functions important in human disease.
